Demonstrates that PSMC4 promotes low-grade glioma progression, suggesting it as a marker for poor prognosis.
PSMC4 overexpression promotes LGG progression and may be an independent marker of poor prognosis. Targeting PSMC4 can reduce tumor growth and metastasis, providing a promising strategy for LGG treatment. Further research on its regulatory mechanisms and clinical implications is warranted.
No takes yet. Share an insight, caveat, or question.
Ming et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: